GPRC5A exerts its tumor-suppressive effects in breast cancer cells by inhibiting EGFR and its downstream pathway

Yang,Lu; Ma,Tao; Zhang,Jin

doi:10.3892/or.2016.5062

GPRC5A exerts its tumor-suppressive effects in breast cancer cells by inhibiting EGFR and its downstream pathway

Authors:
- Lu Yang
- Tao Ma
- Jin Zhang
View Affiliations

Affiliations: The Third Surgical Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, He Xi, Tianjin 300060, P.R. China
Published online on: September 2, 2016 https://doi.org/10.3892/or.2016.5062
Pages: 2983-2990

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

G-protein-coupled receptor family C group 5 member A (GPRC5A) is a member of the type 3-G protein‑coupling receptor family. Previous studies have observed dysregulated expression of GPRC5A in several malignant diseases which suggests that GPRC5A may participate in tumor progression. However, these results are controversial. In the present study, we explored the biological functions of GPRC5A in breast cancer cells and aimed to uncover the related molecular mechanisms. Our results demonstrated that GPRC5A is a tumor suppressor in EGFR-expressing breast cancer cells. GPRC5A knockdown in EGFR-expressing MDA-MB-231 cells promoted colony formation, cell proliferation, cell migration and invasion, while GPRC5A suppression had no impact on MCF7 cells, which express no EGFR. Furthermore, GPRC5A knockdown enhanced EGF-induced EGFR and its downstream signaling activation. Inhibition of EGFR phosphorylation in MDA-MB-231 cells suppressed the tumorigenic effects of GPRC5A knockdown. Moreover, GPRC5A knockdown exhibited an oncogenic role in MCF7 cells transfected with the EGFR-expressing plasmid. Taken together, our results implicate GPRC5A as a tumor suppressor in breast cancer cells, and GPRC5A exerts its tumor-suppressive function by inhibiting EGFR and its downstream pathway.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
2	Polyak K: Heterogeneity in breast cancer. J Clin Invest. 121:3786–3788. 2011. View Article : Google Scholar : PubMed/NCBI
3	Qin XJ and Ling BX: Proteomic studies in breast cancer (Review). Oncol Lett. 3:735–743. 2012.PubMed/NCBI
4	Sun B, Zhang S, Zhang D, Li Y, Zhao X, Luo Y and Guo Y: Identification of metastasis-related proteins and their clinical relevance to triple-negative human breast cancer. Clin Cancer Res. 14:7050–7059. 2008. View Article : Google Scholar : PubMed/NCBI
5	Teng YH, Tan WJ, Thike AA, Cheok PY, Tse GM, Wong NS, Yip GW, Bay BH and Tan PH: Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: Possible implications for targeted therapy. Breast Cancer Res. 13:R352011. View Article : Google Scholar : PubMed/NCBI
6	Ueno NT and Zhang D: Targeting EGFR in triple negative breast cancer. J Cancer. 2:324–328. 2011. View Article : Google Scholar : PubMed/NCBI
7	Liu M, Mo QG, Wei CY, Qin QH, Huang Z and He J: Platinum- based chemotherapy in triple-negative breast cancer: A meta-analysis. Oncol Lett. 5:983–991. 2013.PubMed/NCBI
8	Yewale C, Baradia D, Vhora I, Patil S and Misra A: Epidermal growth factor receptor targeting in cancer: A review of trends and strategies. Biomaterials. 34:8690–8707. 2013. View Article : Google Scholar : PubMed/NCBI
9	Herbst RS: Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys. 59(Suppl 2): 21–26. 2004. View Article : Google Scholar : PubMed/NCBI
10	Tomas A, Futter CE and Eden ER: EGF receptor trafficking: Consequences for signaling and cancer. Trends Cell Biol. 24:26–34. 2014. View Article : Google Scholar :
11	Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi GN and Ueno NT: Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat. 136:331–345. 2012. View Article : Google Scholar : PubMed/NCBI
12	Bhargava R, Gerald WL, Li AR, Pan Q, Lal P, Ladanyi M and Chen B: EGFR gene amplification in breast cancer: Correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol. 18:1027–1033. 2005. View Article : Google Scholar : PubMed/NCBI
13	Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi GN and Ueno NT: Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat. 136:331–345. 2012. View Article : Google Scholar : PubMed/NCBI
14	Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U and Harbeck N: Triple-negative breast cancer - current status and future directions. Ann Oncol. 20:1913–1927. 2009. View Article : Google Scholar : PubMed/NCBI
15	Corkery B, Crown J, Clynes M and O'Donovan N: Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann Oncol. 20:862–867. 2009. View Article : Google Scholar : PubMed/NCBI
16	Wu Q, Ding W, Mirza A, Van Arsdale T, Wei I, Bishop WR, Basso A, McClanahan T, Luo L, Kirschmeier P, et al: Integrative genomics revealed RAI3 is a cell growth-promoting gene and a novel P53 transcriptional target. J Biol Chem. 280:12935–12943. 2005. View Article : Google Scholar : PubMed/NCBI
17	Tao Q, Fujimoto J, Men T, Ye X, Deng J, Lacroix L, Clifford JL, Mao L, Van Pelt CS, Lee JJ, et al: Identification of the retinoic acid-inducible Gprc5a as a new lung tumor suppressor gene. J Natl Cancer Inst. 99:1668–1682. 2007. View Article : Google Scholar : PubMed/NCBI
18	Kadara H, Fujimoto J, Men T, Ye X, Lotan D, Lee JS and Lotan R: A Gprc5a tumor suppressor loss of expression signature is conserved, prevalent, and associated with survival in human lung adenocarcinomas. Neoplasia. 12:499–505. 2010. View Article : Google Scholar : PubMed/NCBI
19	Lin X, Zhong S, Ye X, Liao Y, Yao F, Yang X, Sun B, Zhang J, Li Q, Gao Y, et al: EGFR phosphorylates and inhibits lung tumor suppressor GPRC5A in lung cancer. Mol Cancer. 13:2332014. View Article : Google Scholar : PubMed/NCBI
20	Zhong S, Yin H, Liao Y, Yao F, Li Q, Zhang J, Jiao H, Zhao Y, Xu D, Liu S, et al: Lung tumor suppressor GPRC5A binds EGFR and restrains its effector signaling. Cancer Res. 75:1801–1814. 2015. View Article : Google Scholar : PubMed/NCBI
21	Sokolenko AP, Bulanova DR, Iyevleva AG, Aleksakhina SN, Preobrazhenskaya EV, Ivantsov AO, Kuligina ES, Mitiushkina NV, Suspitsin EN, Yanus GA, et al: High prevalence of GPRC5A germline mutations in BRCA1-mutant breast cancer patients. Int J Cancer. 134:2352–2358. 2014. View Article : Google Scholar : PubMed/NCBI
22	Ma T, Yang L and Zhang J: MiRNA-542–3p downregulation promotes trastuzumab resistance in breast cancer cells via AKT activation. Oncol Rep. 33:1215–1220. 2015.PubMed/NCBI
23	Chaffer CL and Weinberg RA: A perspective on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
24	Lamouille S, Xu J and Derynck R: Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 15:178–196. 2014. View Article : Google Scholar : PubMed/NCBI
25	Cheng Y and Lotan R: Molecular cloning and characterization of a novel retinoic acid-inducible gene that encodes a putative G protein-coupled receptor. J Biol Chem. 273:35008–35015. 1998. View Article : Google Scholar : PubMed/NCBI
26	Tao Q, Cheng Y, Clifford J and Lotan R: Characterization of the murine orphan G-protein-coupled receptor gene Rai3 and its regulation by retinoic acid. Genomics. 83:270–280. 2004. View Article : Google Scholar : PubMed/NCBI
27	Mayer IA, Abramson VG, Lehmann BD and Pietenpol JA: New strategies for triple-negative breast cancer--deciphering the heterogeneity. Clin Cancer Res. 20:782–790. 2014. View Article : Google Scholar : PubMed/NCBI
28	Taurin S, Allen KM, Scandlyn MJ and Rosengren RJ: Raloxifene reduces triple-negative breast cancer tumor growth and decreases EGFR expression. Int J Oncol. 43:785–792. 2013.PubMed/NCBI